Lingfang Xia

机构：Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center · ORCID：0000-0002-4423-1615

发表论文 48 篇 · 总被引 801 次 · h-index 21

代表论文

• Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer (2021 · 癌症：英文版 · 被引 60)
• Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study (2022 · Journal for ImmunoTherapy of Cancer · 被引 39)
• Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study (2023 · International Journal of Gynecological Cancer · 被引 28)
• A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma (2022 · Nature Communications · 被引 27)
• The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer (2023 · Cancer Letters · 被引 26)
• HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway (2021 · Oncogene · 被引 26)